Identifying altered drug targets involves a combination of techniques including genomic sequencing, proteomics, and bioinformatics. Researchers analyze tumor samples to uncover genetic mutations, chromosomal rearrangements, and changes in gene expression that are unique to cancer cells. Advanced technologies, such as next-generation sequencing, have revolutionized this process, enabling the rapid identification of novel targets.
